Have you been diagnosed with Parkinson's disease within the past three years? If so, you may be eligible to participate in a new clinical trial study at UAB.
The University of Alabama at Birmingham's Department of Physical Therapy is seeking volunteers to participate in a clinical research trial to learn more about the effects of aerobic exercise on people with Parkinson's disease. The Principal Investigator is Christopher Hurt, Ph.D.
"Every day, we see how exercise helps those with movement disorders manage their symptoms well," says PAA Care Navigator, Brooklyn White. "This study gives UAB a chance to prove it. Also, this could be an excellent way to remain accountable to exercise while making a positive impact on clinical research, especially for those that prefer a minimal or no medication approach to Parkinson's treatment in earlier stages."
SPARX3 is a research study to learn more about the effects of aerobic exercise on people with Parkinson's disease who have not yet started medication for their PD. It will compare the effects of moderate intensity treadmill exercise to high intensity treadmill exercise on the signs and symptoms of Parkinson's disease.
As a benefit of participating, you will receive information regarding your health status at no cost. This includes a:
You may be eligible to participate if you:
Are between 40 to 80 years old
Have been diagnosed with Parkinson's no more than three years ago
Not currently taking any PD medication or expect to start taking PD medications within the next six months
Be able and willing to do moderate to high intensity exercise on a treadmill four (4) times a week for 18 months and participate in study visits for 24 months
Be able to travel to UAB periodically for study related visits
If you or someone you know would like further information regarding this research study, please contact the study coordinator at 1.205.934.8517.
This study is funded by the National Institute of Neurological Disorders and Stroke. Participants are being recruited under the study number: IRB-300007184.